Brief: Oculis Announces First Patient First Visit In Phase 2B Relief Trial Of Dry Eye Disease Drug

Oculis Holding AG

07/12/2023 12:40

Dec 7 (Reuters) - Oculis Holding AG  CR5.F :
    * OCULIS ANNOUNCES FIRST PATIENT FIRST VISIT IN PHASE 2B
RELIEF
TRIAL OF TOPICAL ANTI-TNFΑ LICAMINLIMAB (OCS-02) IN DRY EYE
DISEASE
    * OCULIS HOLDING AG - TRIAL WAS INITIATED AS PLANNED WITH
TOPLINE
RESULTS EXPECTED IN MID-2024

Source text for Eikon:  ID:nGNX8llYgr 
Further company coverage:  CR5.F 

 ((reuters.briefs@thomsonreuters.com;))